Viva Biotech Reports 2026 Interim Results: Revenue Grows 21%

Viva Biotech announced its interim results for the period ending June 30, 2026, on August 26, 2026. The company reported revenue of RMB1,006.5 million, marking a 21.0% increase compared to the same period last year. However, gross profit rose by a more modest 0.7% to RMB341.7 million, resulting in a gross profit margin of 34.0%.

The company statement indicated that the integration of artificial intelligence (AI) is ushering in a new paradigm in drug research and development. Furthermore, Viva Biotech highlighted that its commercial manufacturing services, operating as a Contract Development and Manufacturing Organization (CDMO), have accelerated revenue growth.

Details on the specific impact of AI on R&D outcomes or which CDMO services contributed most significantly to revenue growth were not provided in the release. The report focuses on the financial figures for the first half of 2026.

Viva Biotech is a service provider in the pharmaceutical industry, offering drug discovery and development services, as well as contract manufacturing.